Anfarm Hellas S.A. - Main Component
Active Substance | Strength | Form |
---|---|---|
Acyclovir | 5% (Tubx10g) | Cr.Ext.Us |
Alendronic acid | 70mg | Tab |
Ambroxol HCl | 15mg/5ml (125ml Bottle) | Syr Infant |
Ambroxol HCl | 30mg/5ml (125ml, 250ml Bottles) | Syr |
Amikacin | 500mg/2ml | Inj.Sol |
Amikacin | 1g/4ml | Inj.Sol |
ApixabanUnder Development | 2.5mg/tab & 5mg/tab | F.C.Tabs |
Atorvastatin | 20mg, 40mg | F.C.Tab |
Azithromycin | 500mg/Vial | Pd.Sol.Inf |
Azithromycin | 250mg, 500mg, 600mg | F.C.Tab |
BrivaracetamUnder Development | 10mg/ml | Sol.Inf |
BrivaracetamUnder Development | 10mg/ml | Oral Solution |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr |
Caspofungin | 50mg, 70mg/Vial | Pd.C.So.In |
Cefotaxime | 1g/Vial (IM, IV) | Ps.Inj.Sol |
Ceftaroline FosamilUnder Development | 600mg/vial | Pd.C.So.In |
Ceftazidime/ AvibactamUnder Development | 2 g/0.5 g | Pd.C.So.In |
Ceftriaxone | 1g/Vial (IM, IV) | Ps.Inj.Sol |
Active Substance | Strength | Form |
---|---|---|
Acyclovir | 5% (Tubx10g) | Cr.Ext.Us |
Alendronic acid | 70mg | Tab |
Ambroxol HCl | 15mg/5ml (125ml Bottle) | Syr Infant |
Ambroxol HCl | 30mg/5ml (125ml, 250ml Bottles) | Syr |
Amikacin | 500mg/2ml | Inj.Sol |
Amikacin | 1g/4ml | Inj.Sol |
ApixabanUnder Development | 2.5mg/tab & 5mg/tab | F.C.Tabs |
Atorvastatin | 20mg, 40mg | F.C.Tab |
Azithromycin | 500mg/Vial | Pd.Sol.Inf |
Azithromycin | 250mg, 500mg, 600mg | F.C.Tab |
BrivaracetamUnder Development | 10mg/ml | Sol.Inf |
BrivaracetamUnder Development | 10mg/ml | Oral Solution |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr |
Caspofungin | 50mg, 70mg/Vial | Pd.C.So.In |
Cefotaxime | 1g/Vial (IM, IV) | Ps.Inj.Sol |
Ceftaroline FosamilUnder Development | 600mg/vial | Pd.C.So.In |
Ceftazidime/ AvibactamUnder Development | 2 g/0.5 g | Pd.C.So.In |
Ceftriaxone | 1g/Vial (IM, IV) | Ps.Inj.Sol |
Active Substance | Strength | Form | Market Availability |
---|---|---|---|
Acyclovir | 5% (Tubx10g) | Cr.Ext.Us | Selected Markets |
Alendronic acid | 70mg | Tab | Selected Markets |
Ambroxol HCl | 15mg/5ml (125ml Bottle) | Syr Infant | Selected Markets |
Ambroxol HCl | 30mg/5ml (125ml, 250ml Bottles) | Syr | Selected Markets |
Amikacin | 500mg/2ml | Inj.Sol | International |
Amikacin | 1g/4ml | Inj.Sol | International |
ApixabanUnder Development | 2.5mg/tab & 5mg/tab | F.C.Tabs | Q4 2023 |
Atorvastatin | 20mg, 40mg | F.C.Tab | Selected Markets |
Azithromycin | 500mg/Vial | Pd.Sol.Inf | International |
Azithromycin | 250mg, 500mg, 600mg | F.C.Tab | Selected Markets |
BrivaracetamUnder Development | 10mg/ml | Sol.Inf | Q1 2023 |
BrivaracetamUnder Development | 10mg/ml | Oral Solution | Q2 2023 |
Budesonide | 0.025% (Tubx30g, x50g, x100g) | Cr.Ext.Us | Selected Markets |
Budesonide | 100mcg/Dose (FLx10ml (200 Doses)) | Naspr.Sus | Selected Markets |
Butamirate Citrate | 7.5mg/5ml (200ml Bottle) | Syr | International |
Caspofungin | 50mg, 70mg/Vial | Pd.C.So.In | International |
Cefotaxime | 1g/Vial (IM, IV) | Ps.Inj.Sol | Selected Markets |
Ceftaroline FosamilUnder Development | 600mg/vial | Pd.C.So.In | Q3 2024 |
Ceftazidime/ AvibactamUnder Development | 2 g/0.5 g | Pd.C.So.In | on going |
Ceftriaxone | 1g/Vial (IM, IV) | Ps.Inj.Sol | International |